Sentence examples for attrition of compounds from inspiring English sources

Early testing and comprehension of these properties in drug candidates is considered by many to be the key to enhance early attrition of compounds and therapeutic interventions that do not have the appropriate ADME/Tox profile for clinical use.

The high rate of attrition of compounds requires a constant supply of new approaches (new chemical entities, immunotherapies, repurposed drugs, devices) that can be assessed for efficacy in AD.

This hopefully will have an impact on the attrition rate of compounds failing in clinical trials for the benefit of all.

These projects have been excluded from the present study in light of their inherent uncertainty; statistically, attrition rates of compounds in clinical phase II are as high as 62% [ 64].

Although there has been great progress in understanding the genetics, anatomy and physiology of the mouse, the attrition rate of compounds tested in Phase II clinical trials is still high [ 5], evidencing the lack of a comprehensive knowledge of the molecular differences between mice and humans that limit the translation of mouse studies to humans [ 6].

One of the major problems for the pharmaceutical industry is the late-stage attrition of novel compounds.

Early-stage attrition of candidate therapeutic compounds for cancer is commonplace in today's drug discovery pipelines due to the complexity associated with drug action.

There is historical precedence that industry can identify and remedy significant causes of attrition; inadequate drug metabolism and pharmacokinetics are no longer the primary cause of compound attrition.

For example, multiple studies have explored the benefit of controlling the size, lipophilicity and polarity properties of compounds in terms of reduced likelihood of attrition [4 8, 13 15].

In addition, cardiac toxicity as a result of drug therapy is one of the main causes of compound attrition during drug development and post-marketing withdrawal.

Concerns over cardiac side effects are the largest single cause of compound attrition during pharmaceutical drug development.